The impact of GPCR structures on pharmacology and structure‐based drug design
暂无分享,去创建一个
[1] A. Engel,et al. Atomic-force microscopy: Rhodopsin dimers in native disc membranes , 2003, Nature.
[2] A. Engel,et al. The G protein‐coupled receptor rhodopsin in the native membrane , 2004, FEBS letters.
[3] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[4] J. Wess. Mutational analysis of muscarinic acetylcholine receptors: structural basis of ligand/receptor/G protein interactions. , 1993, Life sciences.
[5] L. Pustilnik,et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. , 1999, The Journal of pharmacology and experimental therapeutics.
[6] Michel Bouvier,et al. A Peptide Derived from a β2-Adrenergic Receptor Transmembrane Domain Inhibits Both Receptor Dimerization and Activation* , 1996, The Journal of Biological Chemistry.
[7] P Ghanouni,et al. Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] A Abrahamsson,et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.
[9] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[10] Krzysztof Palczewski,et al. Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[11] Vsevolod V Gurevich,et al. How and why do GPCRs dimerize? , 2008, Trends in pharmacological sciences.
[12] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[13] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[14] Arup K. Ghose,et al. Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery , 2008 .
[15] Raymond C Stevens,et al. Discovery of new GPCR biology: one receptor structure at a time. , 2009, Structure.
[16] P. Hargrave,et al. Projection structure of frog rhodopsin in two crystal forms. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] J Hoflack,et al. Functional architecture of vasopressin/oxytocin receptors. , 1999, Journal of receptor and signal transduction research.
[18] Gebhard F. X. Schertler,et al. Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.
[19] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[20] Michelle A. Schmidt,et al. To Market, To Market—2004 , 2005 .
[21] Jürg Zimmermann,et al. Potent and Selective Inhibitors of the AbL-Kinase: Phenylaminopyrimidine (PAP) Derivatives. , 1997 .
[22] Tom L. Blundell,et al. Keynote review: Structural biology and drug discovery , 2005 .
[23] K. Palczewski,et al. Activation of rhodopsin: new insights from structural and biochemical studies. , 2001, Trends in biochemical sciences.
[24] F. Nagy,et al. Metabotropic receptors for glutamate and GABA in pain , 2009, Brain Research Reviews.
[25] P Ghanouni,et al. Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor* , 2001, The Journal of Biological Chemistry.
[26] R. Lefkowitz,et al. Crystallizing Thinking about the β2-Adrenergic Receptor , 2008, Molecular Pharmacology.
[27] M. Bouvier,et al. The evasive nature of drug efficacy: implications for drug discovery. , 2007, Trends in pharmacological sciences.
[28] Michèle N Schulz,et al. Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.
[29] R. Wong,et al. Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors , 2008, Molecular Pharmacology.
[30] Robert J. Lefkowitz,et al. A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling , 2007, Proceedings of the National Academy of Sciences.
[31] Christopher J Langmead,et al. Muscarinic acetylcholine receptors as CNS drug targets. , 2008, Pharmacology & therapeutics.
[32] Michel Bouvier,et al. Building a new conceptual framework for receptor heteromers. , 2009, Nature chemical biology.
[33] Oliver P. Ernst,et al. Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.
[34] G. Milligan,et al. Allosteric modulation of heterodimeric G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.
[35] Sebastian Radestock,et al. Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring , 2008, J. Chem. Inf. Model..
[36] N. Blomberg,et al. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. , 2007, Current topics in medicinal chemistry.
[37] M. Wiener,et al. A pedestrian guide to membrane protein crystallization. , 2004, Methods.
[38] R. Vogel,et al. Conformations of the Active and Inactive States of Opsin* , 2001, The Journal of Biological Chemistry.
[39] W. Hendrickson,et al. Expression of recombinant G-protein coupled receptors for structural biology. , 2007, Molecular bioSystems.
[40] D. M. Ryan,et al. Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.
[41] Jürg Zimmermann,et al. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .
[42] D. Fabbro,et al. Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC) , 1996, Archiv der Pharmazie.
[43] Markus G Grütter,et al. Opportunities for structure-based design of protease-directed drugs. , 2006, Current opinion in structural biology.
[44] T. Schwartz,et al. Locating ligand-binding sites in 7TM receptors by protein engineering. , 1994, Current opinion in biotechnology.
[45] T. Blundell,et al. Structural biology and drug discovery. , 2005, Drug discovery today.
[46] Stefano Costanzi,et al. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. , 2008, Journal of the American Chemical Society.
[47] W. Weis,et al. Structural insights into G-protein-coupled receptor activation. , 2008, Current opinion in structural biology.
[48] K. Miller,et al. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. , 2008, Current opinion in drug discovery & development.
[49] D. Heerding,et al. Aminofurazans as potent inhibitors of AKT kinase. , 2009, Bioorganic & medicinal chemistry letters.
[50] Gebhard F. X. Schertler,et al. Projection structure of rhodopsin , 1993, Nature.
[51] M. Burghammer,et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.
[52] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[53] A. Shaw,et al. β1‐, β2‐ and atypical β‐adrenoceptor‐mediated relaxation in rat isolated aorta , 2000 .
[54] C. Altenbach,et al. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation , 2008, Proceedings of the National Academy of Sciences.
[55] J. An,et al. Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.
[56] Yoko Shibata,et al. Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form , 2008, Proceedings of the National Academy of Sciences.
[57] X. Barril,et al. Virtual screening in structure-based drug discovery. , 2004, Mini reviews in medicinal chemistry.
[58] W. Messer. The utility of muscarinic agonists in the treatment of alzheimer’s disease , 2002, Journal of Molecular Neuroscience.
[59] R. Lefkowitz,et al. β-Arrestins and Cell Signaling , 2007 .
[60] W. Hubbell,et al. Rhodopsin and 9-Demethyl-retinal Analog , 2008, Journal of Biological Chemistry.
[61] Campbell McInnes,et al. Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.
[62] S. Hill,et al. Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates , 2007, Trends in pharmacological sciences.
[63] H. Nasrallah,et al. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles , 2008, Molecular Psychiatry.
[64] Krzysztof Palczewski,et al. Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors. , 2006, Current opinion in structural biology.
[65] Bernard Maigret,et al. Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? , 2003, Trends in pharmacological sciences.
[66] J. Kew,et al. Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.
[67] Graeme Milligan,et al. G protein-coupled receptor dimerisation: molecular basis and relevance to function. , 2007, Biochimica et biophysica acta.
[68] T. Schachtman,et al. The role of metabotropic glutamate receptor 5 in learning and memory processes. , 2005, Drug news & perspectives.
[69] B. Kobilka. G protein coupled receptor structure and activation. , 2007, Biochimica et biophysica acta.
[70] K. Jacobson,et al. 125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. , 1995, Molecular pharmacology.
[71] Michelle A. Schmidt,et al. Chapter 32 To Market, To Market – 2006 , 2007 .
[72] V. Hruby,et al. Contribution of the transmembrane domain 6 of melanocortin-4 receptor to peptide [Pro5, DNal (2')8]-gamma-MSH selectivity. , 2009, Biochemical pharmacology.
[73] T. Lamb,et al. Dark adaptation and the retinoid cycle of vision , 2004, Progress in Retinal and Eye Research.
[74] Thomas M Frimurer,et al. Ligand binding and micro-switches in 7TM receptor structures. , 2009, Trends in pharmacological sciences.
[75] Patrick Scheerer,et al. Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.
[76] T. Huber,et al. Rhodopsin's active state is frozen like a DEER in the headlights , 2008, Proceedings of the National Academy of Sciences.
[77] T. Mielke,et al. Electron crystallography reveals the structure of metarhodopsin I , 2004, The EMBO journal.
[78] Willem Soudijn,et al. Allosteric modulation of G-protein-coupled receptors , 2001 .
[79] T. Kenakin,et al. Inverse, protean, and ligand‐selective agonism: matters of receptor conformation , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[80] S. Cumella. To market to market.... , 1991, The Health service journal.
[81] Philip Seeman,et al. Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.
[82] Krzysztof Palczewski,et al. Visual Rhodopsin Sees the Light: Structure and Mechanism of G Protein Signaling* , 2007, Journal of Biological Chemistry.
[83] Wendy A. Warr,et al. Fragment-based drug discovery , 2009, J. Comput. Aided Mol. Des..
[84] M. Bouvier,et al. Conformational Rearrangements and Signaling Cascades Involved in Ligand-Biased Mitogen-Activated Protein Kinase Signaling through the β1-Adrenergic Receptor , 2008, Molecular Pharmacology.
[85] Gianni Chessari,et al. From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.
[86] J. Ballesteros,et al. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. , 2001, Current opinion in drug discovery & development.
[87] Krzysztof Palczewski,et al. G protein-coupled receptor rhodopsin. , 2006, Annual review of biochemistry.
[88] T. Kenakin. Principles: receptor theory in pharmacology. , 2004, Trends in pharmacological sciences.
[89] Leonardo Pardo,et al. Structural models of class a G protein-coupled receptors as a tool for drug design: insights on transmembrane bundle plasticity. , 2007, Current topics in medicinal chemistry.
[90] Kurt Kristiansen,et al. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. , 2004, Pharmacology & therapeutics.
[91] L. Prézeau,et al. The activation mechanism of class-C G-protein coupled receptors , 2004 .
[92] J. Violin,et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. , 2007, Proceedings of the National Academy of Sciences of the United States of America.
[93] Robert J. Lefkowitz,et al. Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A , 1997, Nature.
[94] Manfred Burghammer,et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. , 2007, Nature.
[95] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[96] R. Stevens,et al. GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.
[97] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[98] Jun Zhang,et al. Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists , 2008, Molecular Pharmacology.
[99] Krzysztof Palczewski,et al. Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes* , 2003, Journal of Biological Chemistry.
[100] Krzysztof Palczewski,et al. Crystal packing analysis of Rhodopsin crystals. , 2007, Journal of structural biology.
[101] Marta Filizola,et al. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[102] T. Kuroki,et al. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. , 2008, Progress in brain research.
[103] R. Lefkowitz,et al. Beta-arrestins and cell signaling. , 2007, Annual review of physiology.
[104] A. Desmyter,et al. Structural genomics on membrane proteins: comparison of more than 100 GPCRs in 3 expression systems , 2007, Journal of Structural and Functional Genomics.